Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on designing and delivering innovative cancer immunotherapy products for cancer patients. We are committed to redefining the treatment landscape for solid tumors by utilizing our proprietary cell therapy platform, which harnesses a patient’s own cells to combat cancer. With cutting-edge technology, we engineer personalized T-cell receptors (TCRs) to target tumor-specific antigens, thus providing tailored treatment options that aim to improve patient outcomes.

In our pursuit to revolutionize cancer therapy, we have developed a robust pipeline of advanced therapies that includes SPEAR T-cells, which are designed to offer new avenues for treatment. Our comprehensive capabilities encompass research, clinical development, manufacturing, and commercialization, positioning us at the forefront of the biopharmaceutical industry. As of 2023, Adaptimmune has achieved significant milestones, including the submission of our Biologics License Application (BLA) for afami-cel in treating synovial sarcoma, demonstrating our commitment to advancing health care for patients with challenging tumors. With strong ties to leading academic institutions and an integrated operational model, we strive to deliver impactful cell therapies that reshape cancer care for patients worldwide.